India, May 12 -- BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data from studies of Voxzogo in children with achondroplasia and other skeletal conditions.
Voxzogo is already approved for the treatment of children with achondroplasia, a genetic bone growth disorder that leads to short-limbed dwarfism.
New data from the Phase 2 CANOPY studies showed that treatment with Voxzogo improved tibial bowing, a common cause of pain and impaired function.
These data were presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark and will be shared at the Pediatric Endocrine Society Annual Meeting (PES) in National Harbor, Maryland....